Resonant Capital Advisors, LLC Exact Sciences Corp Transaction History

Resonant Capital Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	BUY	$56.27 - $73.77 $6,808 - $8,926	121 Added 3.81%	3,296 $227,000
Q4 2023 Jan 31, 2024	SELL	$59.06 - $75.72 $2,126 - $2,725	-36 Reduced 1.12%	3,175 $234,000
Q3 2023 Oct 31, 2023	BUY	$65.94 - $99.04 $211,733 - $318,017	3,211 New	3,211 $219,000
Q2 2022 Jul 12, 2022	SELL	$35.61 - $76.23 $146,891 - $314,448	-4,125 Closed	0 $0
Q1 2022 Apr 19, 2022	BUY	$57.56 - $82.54 $57 - $82	1 Added 0.02%	4,125 $312,000
Q4 2021 Jan 26, 2022	BUY	$72.5 - $100.68 $298,990 - $415,204	4,124 New	4,124 $321,000
Q1 2021 Apr 28, 2021	SELL	$116.57 - $155.01 $401,583 - $534,009	-3,445 Closed	0 $0
Q3 2020 Nov 03, 2020	SELL	$72.92 - $102.01 $496,293 - $694,280	-6,806 Reduced 66.39%	3,445 $351,000
Q2 2020 Aug 05, 2020	BUY	$55.75 - $92.75 $62,495 - $103,972	1,121 Added 12.28%	10,251 $891,000
Q1 2020 May 14, 2020	BUY	$37.9 - $104.44 $6,822 - $18,799	180 Added 2.01%	9,130 $530,000
Q4 2019 Feb 18, 2020	BUY	$77.66 - $99.74 $695,057 - $892,673	8,950 New	8,950 $828,000

610

166M

1.93M

1.23M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $12.1B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Resonant Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Resonant Capital Advisors, LLC with notifications on news.